MARK2 and pachyonychia congenita: In prostate cancer, CCL2 has been reported to directly induce proliferation and migration of PC cell lines via activation of phosphoinostitide-3-kinase (PI3K)/serine-threonine kinase (Akt) signaling [16].This led us to consider CCL2 as a potentially useful PC biomarker.